

[x](#)

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
 - For example, a search on Aminosalicyclic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
 - A search for “Aminosalicyclic Acid Tablets” will result in anything that specifically contains “Aminosalicyclic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
 - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:** You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
---------------------------------	-------------------------	------------------------------------	-----------------------------	----------------------------------	--------------------------------------	---	---	-----------------------------

[Sort ascending](#)

—

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort ascending	Description
TRIAZOLAM TABLETS	<i>Uniformity of dosage units <905></i>	USP41–NF36	4202	28-Dec-2018	1-Jan-2019	NA	NA	In <i>Mobile phase</i> and <i>Chromatographic system</i> : Change Proceed as directed in the Assay under <i>Triazolam</i> . to: Proceed as directed in the Assay. AND In <i>Procedure</i> : Change Proceed as directed for <i>Procedure</i> in the Assay under <i>Triazolam</i> . to: Proceed as directed in the Assay.
CLOMIPHENE CITRATE	ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	USP42–NF37	1068	31-May-2019	1-Jun-2019	NA	NA	In USP Clomiphene Related Compound A RS: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	(E,Z)-2-[4-(1,2-Diphenylethyl)phenoxy]-N,N-diethylethanamine hydrochloride. to: (E,Z)-2-[4-(1,2-Diphenylvinyl)phenoxy]-N,N-diethylethanamine hydrochloride. Also known as (E,Z)-2-[4-(1,2-Diphenylethenyl)phenoxy]-N,N-diethylethanamine hydrochloride. In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-
FEXOFENADINE HYDROCHLORIDE TABLETS	ADDITIONAL REQUIREMENT S/USP Reference	Revision Bulletin (Official November 01, 2018)	Online	30-Aug-2019	1-Sep-2019	NA	NA	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl.
EPINEPHRINE	IM PURITIES/ <i>Enantiomeric Purity</i>	USP43–NF38	Online	24-Apr-2020	1-May-2020	NA	NA	This erratum applies to the USP-NF ONLINE platform only. In <i>System suitability solution</i>: Change 0.03 mg/mL of in <i>Mobile phase</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication _Sort ascending	Description
						—	to: 0.03 mg/mL of USP Racepinephrine Hydrochloride RS in <i>Mobile phase</i> In <i>Procedure</i> : Change 694.83/676.83)(250) $C_A(r_U/r_S)$ in which 694.83 and 676.83 are the molecular weights of atropine sulfate monohydrate and anhydrous atropine sulfate, respectively; to: (694.84/676.82) (250) $C_A(r_U/r_S)$ in which 694.84 and 676.82 are the molecular weights of atropine sulfate monohydrate and anhydrous
DIPHENOXYLA Assay TE HYDROCHL ORIDE AND ATROPINE SULFATE TABLETS	USP43–NF38	1439	26-Jun-2020	1-Jul-2020	NA	NA	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	
DRY HEAT DE INTRODUCTION	INTRODUCTION	USPNF Online	Online	23-Feb-2024	1-Mar-2024	NA	NA	atropine sulfate, respectively; Change parental manufacturing to: parenteral manufacturing
CARVEDILOL	IMPURITIES/Organic Impurities, Procedure 2	USP43–NF38	Online	18-Dec-2020	1-Jan-2021	NA	NA	In Table 3/footnote b: Change 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(6,7,8,9-tetrahydro-5H-carbazol-4-yl)propan-2-ol. to: 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(2,3,4,9-tetrahydro-1H-carbazol-5-yl)propan-2-ol. Please see the updated
DACTINOMYCIN	CHEMICAL INFORMATION	USP43–NF38	Online	25-Jun-2021	1-Jul-2021	NA	NA	

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending	
						—	chemical structure at online.uspnf.com
ONDANSETRON	USP Reference Standards <11> ISSUE 1	USPNF 2021 Online	31-Dec-2021	1-Jan-2022	NA	NA	Change USP Ondansetron RS USP Ondansetron Related Compound C RS 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one . USP Ondansetron Related Compound D RS 1,2,3,9-Tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one

Monograph TitleSection	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending	
						—	. to: USP Ondansetron RS USP Ondansetron Related Compound A RS 3-[(Dimethylami no)methyl]-9-m ethyl-1,2,3,9-tet rahydr o-4 <i>H</i> -carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 9-Methyl-1,2,3,9 -tet rahydr o-4 <i>H</i> -carbazol-4-one . USP Ondansetron

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	Related Compound D RS 9-Methyl-3-methyl-1,2,3,9-tetrahydro-4H-carbazol-4-one
IVERMECTIN	CHEMICAL INFORMATION	USPNF Online	Online	24-Jun-2022	1-Jul-2022	NA	NA	Change $C_{48}H_{74}O_{14}$ (Component H_2B_{1a}) 875.09 $C_{47}H_{72}O_{14}$ (Component H_2B_{1b}) 861.07 Component H_2B_{1a} : Avermectin A_{1a} , 5-O-demethyl-22,23-dihydro-, (2aE,4E,8E)-(5?S,6S,6?R,7S,11R,13R,15S,17aR,20R,20aR,20bS)-6?-(S)-sec-Butyl-3?,4?,5?,

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending	
						—	6,6?,7,10,11,14,15,17a,20,20a,20b-tetradecahydro-20,20b-dihydroxy[11,15-methano-2 <i>H</i> ,13 <i>H</i> ,17 <i>H</i> -furo[4,3,2- <i>pq</i>][2,6]benzodioxacyclooctadecin-13,2?-[2 <i>H</i>]pyran]-7-yl 2,6-di deoxy-4- <i>O</i>
							<i>O</i> -methyl-?- <i>L</i> -arabino-hexopyranosyl)-3- <i>O</i> -methyl-?- <i>L</i> -arabino-hexopyranoside CAS RN®:

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending	
						—	70161-11-4. Component H ₂ B _{1b} : Avermectin A _{1a} , 5-O -demethyl-25-d e(1-methylpropy l)-22,23-dihydro -25-(1-methylet hyl)-. (2a <i>E</i> ,4 <i>E</i> ,8 <i>E</i>)-(5? <i>S</i> ,6 <i>S</i> ,6? <i>R</i> ,7 <i>S</i> ,11 <i>R</i> ,13 <i>R</i> ,15 <i>S</i> ,17a <i>R</i> ,20 <i>R</i> ,20a <i>R</i> ,20b <i>S</i>)-3?,4?,5?,6,6?, 7,10,11,-oxospir o[11,15-methan o-2 <i>H</i> ,13 <i>H</i> ,17 <i>H</i> -furo[4,3,2- <i>pq</i>][2,6]benzodiox acyclooctadecin -13,2?[2 <i>H</i>]pyran]-7-yl 2, 6-di deoxy- 4-O

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending	
						—	O -me thyl-?- L- <i>arabino</i> -hexopyranosyl) -3-O-methyl-?- L- <i>arabino</i> -hexopyranosid e CAS RN®: 70209-81-3; UNII: 0W28CYI3TU. to: C₄₈H₇₄O₁₄ (Component H₂B_{1a}) 875.11 C₄₇H₇₂O₁₄ (Component H₂B_{1b}) 861.08 Component H₂B_{1a}: Avermectin A_{1a}, 5-O -demethyl-22,23 -dihydro-. (2aE,4E,8E

Monograph TitleSection	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending —	)-(5'S,6S,6'R ,7S,11R,13R ,15S,17aR ,20R,20aR ,20bS)-6'-(S)- sec -Butyl-3',4',5', 6,6',7,10,11,14, 15,17a,20,20a,2 0b-tetradecahyd ro-20,20b-dihyd roxy-5',6,8,19-t etramethyl-17-o xospiro [11,15- meth ano-2 <i>H</i> ,13 <i>H</i> ,17 <i>H</i> -furo[4,3,2- <i>pq</i>][2,6]benzodiox acyclooctadecin -13,2'-[2 <i>H</i>]pyran]-7-yl 2, 6-di deoxy- 4- <i>O</i> O

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	-me thyl-?- L- <i>arabino</i> -hexopyranosyl) -3-O-methyl-?- L- <i>arabino</i> -hexopyranosid e CAS RN®: 71827-03-7; UNII: 91Y2202OUW. Component H ₂ B _{1b} : Avermectin A _{1a} , 5-O -demethyl-25-d e(1-methylpropy l)-22,23-dihydro -25-(1-methylet hyl)-. (2aE,4E,8E)-(5'S,6S,6'R ,7S,11R,13R ,15S,17aR ,20R,20aR ,20bS)-3',4',5',6,6', 7,10,11,14,15,1

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending	
						—	7a,20,20a,20b-Tetradecahydro-20,20b-dihydroxy-6'-isopropyl-5',6,8,19-tetramethyl-17-oxopiro [11,15-methano-2 <i>H</i> ,13 <i>H</i> ,17 <i>H</i>]-furo[4,3,2- <i>pq</i>][2,6]benzodioxacyclooctadecin-13,2'-[2 <i>H</i>]pyran]-7-yl 2,6-di deoxy-4- <i>O</i> - <i>O</i> - <i>me</i> thyl-?- <i>L</i> - <i>arabino</i> -hexopyranosyl)-3- <i>O</i> -methyl-?- <i>L</i> - <i>arabino</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication _Sort ascending	Description
						—	-hexopyranoside CAS RN®: 70209-81-3; UNII: 0W28CYI3TU. In <i>Solution A</i> : Change 0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well. to: 0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of 0.5 N hydrochloric
CALCIUM UND ASSAY/ ECYLENATE <i>Procedure</i>	USPNF Online Online		28-Oct-2022	1-Nov-2022	NA	NA	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	acid VS to a 500-mL volumetric flask, dilute with water to volume, and mix well.
ACARBOSE TABLETS	IDENTIFICATION	USP <i>NF Online</i>	Online	28-Apr-2023	1-May-2023	NA	NA	Change The spectrum obtained from the <i>Sample solution</i> shows IR maxima in the regions of 3500–3200, 2950–2890, 1653–1633, and 1070–1000 cm ⁻¹ . to: The spectrum obtained from the sample preparation shows IR maxima in the regions of 3500–3200, 2950–2890, 1653–1633, and 1070–1000

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort ascending	Description
VALGANCICLO IMPURITIES VIR HYDROCH LORIDE	USPNF Online	Online	25-Aug-2023	1-Sep-2023	NA	NA	cm ⁻¹ . In <i>Organic Impurities/Table 3</i> /footnote c: Change 2-[(2-Amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]-2-hydroxypropyl methyl-L-valinate hydrochloride. to: 3-[(2-Amino-6-oxo-1,6-dihydropurin-9-yl)methoxy]-2-hydroxypropyl L-valinate hydrochloride. Change The retention time of the major peak of the <i>Sample solution</i> corresponds to that of the <i>Sample solution</i> , as
METAXALONE IDENTIFICATIO N/B.	USP41–NF36	2611	29-Mar-2019	1-Apr-2019	NA	NA	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	obtained in the Assay. to: The retention time of the major peak of the <i>Sample solution</i> corresponds to that of the <i>Standard solution</i> , as obtained in the Assay.
SODIUM BICARBONATE	IM PURITIES/ <i>Carbonate</i>	<i>USP42–NF37</i>	4019	28-Jun-2019	1-Jul-2019	NA	NA	In <i>Analysis</i> : Change and promptly add 10 g of sodium bicarbonate to: and promptly add 10 g of Sodium Bicarbonate
2,5-DIHYDROXYBENZOIC ACID	REAGENTS AND REFERENCE TABLES/ <i>Reagent</i>	<i>USP42–NF37</i>	6097	22-Nov-2019	1-Dec-2019	NA	NA	Change [303-07-1]. to: [490-79-9].

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	
POLYOXYL 35 CASTOR OIL	<i>Specifications</i> IDENTIFICATION N/C. <i>Identity by Fatty Acid Composition</i>	USP43–NF38	5956	24-Apr-2020	1-May-2020	NA	NA	In System suitability/Suitability requirements/Relative standard deviation: Change linoleate to: linoleate
TELMISARTAN TABLETS	IDENTIFICATION N/A.	USP43–NF38	4240	25-Sep-2020	1-Oct-2020	NA	NA	Change Spectroscopic Identification Tests ?197?, Ultraviolet Spectroscopy: 197U: to: Spectroscopic Identification Tests ?197?, Ultraviolet-Visible Spectroscopy: 197U:
THE DISSOLUTION PROCEDURE: DEVELOPMENT AND	1. PRELIMINARY ASSESSMENT	<i>Second Supplement to USP43–NF38</i>	Online	20-Nov-2020	1-Dec-2020	NA	NA	In paragraph 4 of 1.4 Choosing an apparatus: Change peak vessels

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	
VALIDATION								to:
MIRTAZAPINE TABLETS	ADDITIONAL REQUIREMENT <i>S/USP Reference Standards <11></i>	USP43–NF38	Online	26-Mar-2021	1-Apr-2021	NA	NA	apex vessels In USP Mirtazapine Resolution Mixture RS: Change Impurity D: 1,2,3,4,10,14b-Hexahydro pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine . to: Impurity D: [Note—This impurity may be available either as the free base form or as the hydrochloride salt form.] 1,2,3,4,10,14b-Hexahydro pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication _Sort ascending	Description
						—	or 1,2,3,4,10,14 b-Hexahydropyr azino[2,1-a]pyri do[2,3-c][2]benzazepine hydrochloride. In <i>Resolution</i> : Change NLT 2.0 between the quetiapine desthoxy and quetiapine peaks to: NLT 2.0 between the quetiapine desethoxy and quetiapine peaks Change USP Ondansetron Related Compound A RS 3-[(Dimethylami
QUETIAPINE E IM XTENDED- RELEASE TABLETS	PUR ITIES/ <i>Organic Impuri ties/System Suitability</i>	USPNF 2021 ISSUE 1 Online	27-Aug-2021	1-Sep-2021	NA	NA	
ONDANSETRO N ORAL SOLUTION	USP Reference standards <11>	USPNF Online Online	25-Mar-2022	1-Apr-2022	NA	NA	

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending	
						—	no)methyl]-1,2,3,9-tetrahydro-9-methyl-4 <i>H</i> -carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 1,2,3,9-Tetrahydro-9-methyl-3-methylene-4 <i>H</i> -carbazol-4-one.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	to: USP Ondansetron Related Compound A RS 3-[(Dimethylami no)methyl]-9-m ethyl-1,2,3,9-tet rahydr o-4 <i>H</i> -carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 9-Methyl-1,2,3,9 -tet rahydr o-4 <i>H</i> -carbazol-4-one . USP Ondansetron Related Compound D RS 9-Methyl-3-met

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication _Sort ascending	Description
							—	hylene-1,2,3,9-tetrahydro-4 <i>H</i> -carbazol-4-one . In <i>Titrimetric system</i> : Change Titrant : Iodine Back-titrant : Sodium thiosulfate to: Titrant : 0.1 N Iodine VS Back-titrant : 0.1 N Sodium Thiosulfate VS Change CAS RN®: 25332-68-3. to: CAS RN®: 25322-68-3.
POTASSIUM GLUCONATE	IMPURITIES/ <i>Reducing Substances</i>	<i>USPNF Online</i>	Online	26-Aug-2022	1-Sep-2022	NA	NA	
POLYETHYLENE GLYCOL STANDARDS WITH MOLECULAR WEIGHTS OF 1000, 2000, 3000, 4000, AND 6000 DALTONS (G/MOL)	CHEMICAL INFORMATION	<i>USPNF Online</i>	Online	27-Jan-2023	1-Feb-2023	NA	NA	
OIL-SOLUBLE	CONTAMINANTS	<i>USP43–NF38</i>	5378	30-Oct-2020	1-Nov-2020	NA	NA	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
VITAMINS WITH MINERALS TABLETS	TS						—	<i>Absence of Specified Microorganisms <2022>, Test Procedures, Test for Absence of Salmonella Species and Absence of Specified Microorganisms <2022>, Test Procedures, Test for Absence of Salmonella Species: to: Absence of Specified Microorganisms <2022>, Test Procedures, Test for Absence of Salmonella Species and Test for Absence of</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication _Sort ascending	Description
MEBENDAZOL <i>Identification</i> E ORAL SUSPENSION	USP43–NF38	2744	20-Nov-2020	1-Dec-2020	NA	NA	<i>Escherichia coli</i> : Change Mix a quantity of Oral Suspension, equivalent to about 200 mg of mebendazole, with 20 mL of a mixture of chloroform and 96 percent formic acid (19:1). Proceed as directed for <i>Identification</i> under <i>Mebendazole</i> <i>Tablets</i> , beginning with “Warm the suspension on a water bath for a few minutes.” The specified result is obtained. to: Mix a quantity of Oral

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending	
						—	Suspension, equivalent to about 200 mg of mebendazole, with 20 mL of a mixture of chloroform and 96 percent formic acid (19:1). Warm the suspension on a water bath for a few minutes, cool, and filter through a medium-porosity, sintered-glass filter. Apply 10 mL of this solution and 10 mL of a <i>Standard solution</i> of USP Mebendazole RS in a mixture of chloroform and 96 percent formic acid (19:1)

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending	
						—	containing 10 mg per mL to a suitable thin-layer chromatographic plate (see <i>Chromatography</i> <621>) coated with a 0.25-mm layer of chromatographic silica gel mixture. Allow the spots to dry, and develop the chromatogram in a solvent system consisting of a mixture of chloroform, methanol, and 96 percent formic acid (90:5:5) until the solvent front has moved about three-fourths of the length of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	plate. Remove the plate from the developing chamber, mark the solvent front, allow the solvent to evaporate, and examine the plate under short-wavelength UV light: the R_F value of the principal spot obtained from the <i>Test solution</i> corresponds to that obtained from the <i>Standard solution</i> .
AMITRIPTYLIN CHEMICAL E HYDROCHLORIDE	INFORMATION	USP43–NF38	Online	28-May-2021	1-Jun-2021	NA	NA	Change 313.86 to: 313.87
ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE	IMPURITIES Organic Impurities	USPNF 2021 ISSUE 1	Online	29-Oct-2021	1-Nov-2021	NA	NA	In <i>Analysis</i> : Change r_S = peak response of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	
TABLETS								alfuzosin from the <i>Sample solution</i> to: r_S = peak response of alfuzosin from the <i>Standard solution</i>
MUPIROCIN CREAM	<i>Related compounds/</i> Table 1	USPNF Online	Online	29-Apr-2022	1-May-2022	NA	NA	In footnote 2: Change 9- <i>{(E)-4-[(2R,3aS,6S,7S,8aRS)-2-<i>{(1RS,2S,3S)-1,3-Dihydroxy-2-methylbutyl}</i>-7-hydroxyhexahydro-2H-furo[3,2-c]pyran-6-yl]-3-methylbut-2-enoyloxy}</i> nonanoic acid.
								to: 9- <i>{(E)-4-[(2R,3aS,6</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	S,7S)-2-{{(1RS,2S ,3S)-1,3-Dihydroxy- 2-methylbutyl}-7 -hydroxyhexahy dro-2H -furo[3, 2-c]pyran-6-yl]-3-m ethylbut-2-enoyl oxy}nonanoic acid. In <i>Hydrochloric acid solution</i> : Change 0.1 N methanolic hydrochloric acid to: 0.01 N methanolic hydrochloric acid Change Proceed with Injection as directed in the <i>Assay for</i>
TERAZOSIN CAPSULES	ASSAY/ <i>Procedure</i>	USPNF Online	Online	30-Sep-2022	1-Oct-2022	NA	NA	
LIDOCAINE HY DROCHLORID E AND DEXTROSE INJECTION	<i>Assay for lidocaine hydrochloride</i>	USPNF Online	Online	24-Feb-2023	1-Mar-2023	NA	NA	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	<i>lidocaine hydrochloride under Lidocaine and Epinephrine Injection.</i> to: Proceed with Injection as directed in the Assay for <i>lidocaine hydrochloride under Lidocaine Hydrochloride and Epinephrine Injection.</i>
REAGENTS AND REFERENCE TABLES	<i>Solutions/Test Solutions and Indicator Solutions/Starch TS</i>	USPNF Online	Online	25-Aug-2023	1-Sep-2023	NA	NA	Change Prepare this solution by one of the following procedures: to: Prepare this solution by one of the following procedures. Apply the <i>Test for sensitivity</i> to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	confirm suitability for freshly or previously prepared solutions or commercially bought solutions. AND In <i>Storage</i> : Delete Use the <i>Test for sensitivity</i> to confirm suitability for use. AND In <i>Procedure with No Preservative</i> : Delete Apply the <i>Test for sensitivity</i> to confirm suitability for freshly or previously prepared solutions.

Monograph TitleSection	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending —	AND In <i>Test for sensitivity</i> : Delete Use the <i>Test for sensitivity</i> to confirm suitability for use. AND In <i>Procedure with Salicylic Acid as Preservative</i> : Change Mix 1 g of soluble starch with 50 mL of cold water to: Mix 1 g of soluble starch with 5 mL of cold water In <i>USP Reference Standards</i> ?11?/USP Iodixanol Related
IODIXANOL INJECTION	ADDITIONAL REQUIREMENTS	USP ^{NF} Online	23-Feb-2024	1-Mar-2024	NA	NA	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	Compound E RS: Change 5-[[3-[[3-[(2,3-D ihydroxypropyl) amino]carbonyl] -5- [[amino]carb onyl]-2,4,6-triiod ophenyl](acetyli mino)]-2-hydrox ypropyl]-(acetyli mino)]-N,N?-bis (2,3-dihydroxypr opyl)-2,4,6-triiod o-1,3-benzenedi carboxamide. to: 5-{N-[3-(N -{3-Carbamoyl- 5-[(2,3-dihydrox ypropyl)carbam oyl]-2,4,6-triiodo phenyl}acetami do)-2-hydroxypr opyl]acetamido} -N ¹ ,N ³ -bis(2,3-dihydro xypropyl)-2,4,6-t riiodoisophthala mide. In <i>Labeling</i> :
SALIX	ADDITIONAL R	USP42–NF37	5189	25-Jan-2019	1-Feb-2019	NA	NA	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
SPECIES	EQUIREMENT						—	Change
BARK	S							The label states the Latin binomial(s) of one or several <i>Salix</i> species included in the article.
POWDER								to: The label states the Latin binomial(s) of one or several <i>Salix</i> species included in the article. Dosage forms prepared with this article should bear the following statement: Not for use in children, women who are pregnant or nursing, or by persons with known sensitivity to aspirin.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	AND In <i>USP Reference Standards</i> <11>: Delete (This monograph is postponed indefinitely.)
EPRINOMECTIN	IMPURITIES/Organic Impurities/Acceptance criteria	USP42–NF37	1627	31-May-2019	1-Jun-2019	NA	NA	In <i>Total unknown impurities</i> : Change NMT 1.0 to: NMT 1.0%
BENDAMUSTINE HYDROCHLORIDE FOR INJECTION	ADDITIONAL REQUIREMENTS/USP Reference Standards <11>	USP42–NF37	487	27-Sep-2019	1-Oct-2019	NA	NA	In <i>USP Bendamustine Related Compound B RS</i> : Change 4-(1-Methyl-5-morpholino-1 <i>H</i> -benzimidazol-2-yl)butanoic acid. C ₁₆ H ₂₁ N ₃ O ₃ 303.36 to:

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort ascending	Description
						—	4-(1-Methyl-5-morpholino-1 <i>H</i> -benzimidazol-2-yl)butanoic acid hydrochloride. $C_{16}H_{21}N_3O_3 \cdot x HCl$
PROPRANOLOL HYDROCHLORIDE IM L HYDROCHLORIDE RIDE ITIES/ <i>Organic Impurities</i>	USP43–NF38	3746	24-Apr-2020	1-May-2020	NA	NA	In System suitability/Suitability requirements/Relative standard deviation: Change NMT 5.0, to: NMT 5.0%,
SOTALOL HYDROCHLORIDE Identification TABLETS	USP43–NF38	4105	31-Jul-2020	1-Aug-2020	NA	NA	Change Weigh and powder a quantity of the Tablets, equivalent to about 250 mg of sotalol

Monograph TitleSection	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending —	hydrochloride, and transfer to a 50-mL volumetric flask. Add 25 mL of methanol, and shake for 10 minutes. Dilute with methanol to volume, mix, and filter: the filtrate so obtained meets the requirements for <i>Identification</i> test B under <i>Sotalol Hydrochloride</i> . to: <i>Thin-Layer Chromatographic Identification Test</i> <201>— <i>Test solution</i> —Weigh and powder a quantity of the Tablets, equivalent to

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending	
						—	about 250 mg of sotalol hydrochloride, and transfer to a 50-mL volumetric flask. Add 25 mL of methanol, and shake for 10 minutes. Dilute with methanol to volume, mix, and filter. Use the filtrate. <i>Developing solvent system:</i> a mixture of chloroform and methanol (70:30). <i>Procedure</i>—Proceed as directed in the chapter, except to place two 25-mL beakers, each containing about 10 mL of ammonium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	hydroxide, on the bottom of the chromatographic chamber that is lined with filter paper and contains the <i>Developing solvent system</i> , allow to equilibrate for 15 minutes, then place the plate in the chamber, and develop the chromatograms until the solvent front has moved about two-thirds of the length of the plate: meets the requirements. In the first variable definition list in <i>Analysis: Change</i> 522.93
AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS	IM PUR ITIES/ <i>Organic Impurities</i>	USP43–NF38	Online	26-Feb-2021	1-Mar-2021	NA	NA	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	
GEMCITABINE FOR INJECTION	ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	USP43–NF38	2094	30-Jul-2021	1-Aug-2021	NA	NA	to: 522.94 In USP Cytosine RS: Change 2(1H)-Pyrimidinone, 4-amino-.
ONDANSETRON INJECTION	USP Reference standards <11>	USPNF Online	Online	28-Jan-2022	1-Feb-2022	NA	NA	to: Cytosine. In USP Ondansetron Related Compound A RS: Change 3-[(Dimethylamino)methyl]-1,2,3, ,9-tetrahydro-9-methyl- 4H -carbazol-4-one hydrochloride. to: 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro- 4H -carbazol-4-one hydrochloride.

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
						Sort ascending	
						—	AND In USP Ondansetron Related Compound C RS: Change 1,2,3,9-Tetrahy d ro- 9-me thyl-4<i>H</i> -carbazol-4-one . to: 9-Methyl-1,2,3,9 -tet rahydr o-4<i>H</i> -carbazol-4-one . AND In USP Ondansetron Related Compound D RS: Change 1,2,3,9-Tetrahy dro-9-methyl-3- met hylene-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	4H -carbazol-4-one . to: 9-Methyl-3-met hylene-1,2,3,9-t etra hydro-4H -carbazol-4-one .
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE TABLETS	IMPURITIES/ <i>Limit of Homatropine Hydrobromide and Related Substances</i>	USPNF Online	Online	24-Jun-2022	1-Jul-2022	NA	NA	In Buffer: Change Adjust with phosphoric acid to a pH of 6.4 ± 0.01. to: Adjust with phosphoric acid to a pH of 6.4 ± 0.1.
FLUVOXAMINE MALEATE TABLETS	ASSAY/ <i>Procedure</i>	USPNF Online	Online	28-Apr-2023	1-May-2023	NA	NA	In Solution A: Change 8 g/L of 1-penta nesulfonic acid sodium salt and 1 g/L of monobasic potassium phosphate in

Monograph Title Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication _Sort ascending	Description
						—	water. to: 8 g/L of 1-penta nesulfonic acid sodium salt and 1.1 g/L of monobasic potassium phosphate in water. In <i>Proce dure/System suitabil ity/Suitability requirements:</i> Change Resolution: NLT 3 between telmisartan and telmisartan related compound A Tailing factor: NMT 2.0 for the telmisartan peak Capacity factor: NLT 1.5
TELMISARTAN ASSAY TABLETS	USPNF Online Online		27-Oct-2023	1-Nov-2023	NA	NA	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	Relative standard deviation: NMT 2.0% to: Resolution: NLT 3 between telmisartan and telmisartan related compound A Tailing factor: NMT 2.0 for telmisartan Relative standard deviation: NMT 2.0% for telmisartan In USP Levalbuterol Related Compound D RS: Change 5-{2-[(1,1-Dimethylethyl)amino]-1-hydroxyethyl}-2-hydroxybenzaldehyde.
LEVALBUTEROL HYDROCHLORIDE	ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	USP42–NF37	2518	26-Apr-2019	1-May-2019	NA	NA	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	$C_{13}H_{19}NO_3$ 237.29 ?[NOTE—This may be available as the sulfate salt (2:1).] (USP 1-May-2019) to: 5-[2-(<i>tert</i>-Butylamino)-1-hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1) (salt); Also known as 5-[2-[(1,1-Dimethyl)ethyl]amino]-1-hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1). $(C_{13}H_{19}NO_3)_2 \cdot H_2SO_4$ 572.67 Change cfu/g to: cfu/mL
ALUMINA, MAGNESIA, AND SIMETHICONE ORAL SUSPENSION	SPECIFIC TESTS/ <i>Microbial Enumeration Tests</i> <61> and <i>Tests for</i>	USP42–NF37	170	26-Jul-2019	1-Aug-2019	NA	NA	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
							—	
INSULIN ASSAYS	Specified Microorganisms <62> ASSAY/Rabbit Revision Blood Sugar Method—Quantitative	Online		27-Dec-2019	1-Jan-2020	NA	NA	In Standard stock solution: Change of USP Insulin RS of the appropriate species to: of the USP Insulin Reference Standard of the appropriate species AND In Sample stock solution: Change of USP Insulin RS of the appropriate species. to: of the USP Insulin Reference Standard of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Sort ascending	
PRAVASTATIN SODIUM	ADDITIONAL REQUIREMENTS	USP43–NF38	3645	29-May-2020	1-Jun-2020	NA	NA	appropriate species. In <i>USP Reference Standards</i> <11>/ <i>USP Pravastatin Related Compound A</i> RS: Change 446.51 to: 446.52
REAGENTS AND REFERENCE TABLES	REAGENT SPECIFICATIONS	USP42–NF37	6079	26-Apr-2019	1-May-2019	NA	NA	In <i>Beef Extract/ Microbial Content</i> : Change MT to: NMT
LOVASTATIN TABLETS	PERFORMANCE TESTS/ <i>Dissolution</i> <711>	<i>First Supplement to</i> USP42–NF37	8727	26-Jul-2019	1-Aug-2019	NA	NA	In <i>Mobile phase</i> : Change Processed as directed in the Assay to: Proceed as directed in the Assay.

Pagination

- [_ First page « First](#)
- [_ Previous page < Previous](#)
- ...
- [_ Page 15](#)
- [_ Page 16](#)
- [_ Page 17](#)
- [_ Page 18](#)
- [_ Current page 19](#)
- [_ Page 20](#)
- [_ Page 21](#)
- [_ Page 22](#)
- [_ Page 23](#)
- ...
- [_ Next page Next >](#)
- [_ Last page Last »](#)